Rainbow Coral Corp. (OTCBB: RBCC) received word this week that the revolutionary technology developed by its partner, Nano3D Biosciences (n3D), is set to begin penetrating the U.S. marketplace.
Nano3D announced recently that it signed a distribution agreement with St. Louis-based scientific products distributor MIDSCI to sell its revolutionary BioAssembler product line in the multi-billion-dollar U.S biotechnology market.
The BioAssembler is a ground-breaking system that allows researchers to culture cells in three dimensions, creating lifelike tissues that are incredibly similar to those found within the body. Under the new agreement, MIDSCI will market and sell BioAssembler technology to life sciences researchers in pharmaceutical, biotech, academic and government laboratories.
“With MIDSCI’s focus on the cell culture market in the U.S. and the capabilities of its sales and marketing organization in addressing the needs of the life science researchers in a variety of market segments, this distribution partnership will provide even easier access to our 3D cell culture (technology) for researchers in the U.S.,” said n3D President and CSO Dr. Glauco Souza.
It’s exciting news for RBCC, as well. The company signed a joint venture agreement to help develop and market the BioAssembler last year. There has been an explosion in interest in n3D’s magnetic levitation technology since it became the subject of a feature article in Nature, the world’s premiere science journal.
“This deal with MIDSCI is a major step forward in turning this revolutionary technology into the global standard in cellular research,” said RBCC CEO Patrick Brown.
For more information on RBCC’s partnership with n3D and other biotech initiatives, please visit www.rainbowbiosciences.com/investors.html.
Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN).
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Patrick Brown, 850-269-7230
President and CEO
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here